Loading…
Hosted by Unknown Host · 🇺🇸 US · EN-US · 128 episodes
Established thought leaders with verified media credentials.
Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created.
Unknown Host hosts The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes, a science show with 128 episodes published.
Amylyx's avexitide cut serious hypoglycemic events 55% in Phase 3, sending shares up 54% to a three-year high - on a drug bought for $35 million out of bankruptcy. We break down BioMarin's $275 million Alesta acquisition
EyePoint stock crashed 67% after Duravyu missed its primary endpoint against aflibercept in the LUGANO Phase 3 for wet AMD - with nine vision-loss cases in the treatment arm versus zero. Also: argenx's Vyvgart Hytrulo hi
Eli Lilly filed six lawsuits over black-market retatrutide and has referred more than 200 sellers to regulators — before it has even filed for approval. Plus Bristol Myers Squibb's accelerated approval of Zenbexus (iberd
BMS won FDA accelerated approval for Zenbexus on a 41% versus 21% MRD-negative complete response — with no survival data required. We break down what the first CELMoD approval means for Bristol Myers' Revlimid replacemen
Definium's DT120 separated from placebo by 5.4 points in Phase 3 generalized anxiety — from a single dose of pharmaceutical-grade LSD. Also: Taiho and Cullinan halt a first-line EGFR exon 20 lung cancer trial early with
DT120 beat placebo by 5.4 points on the Hamilton Anxiety scale twelve weeks after a single dose — the first new mechanism in generalized anxiety disorder since 2007, and the real constraint isn't efficacy, it's who pays
A federal judge blocked the Pentagon's Chinese military designation of WuXi AppTec, finding the DoD's case rested on a misreading. Plus: Sionna Therapeutics' cystic fibrosis failure sends shares down ninety-two percent a
Jazz Pharmaceuticals is paying $820 million upfront — up to $1.3 billion total — for Actio Biosciences and its first-in-class KCNT1 epilepsy drug ABS-1230. Plus: Sionna Therapeutics' SION-719 fails alongside Vertex's Tri
FDA approved Takeda's Orzeyful, a first-in-class orexin-2 agonist for narcolepsy type 1, with peak sales seen near $2B. Also: Replimune's Tudriqev wins accelerated approval with Opdivo in advanced melanoma after two reje
Vedanta Biosciences raised $60M, including $20M from BARDA, to finish the Phase 3 that decides its microbiome bet on VE303 in recurrent C. difficile infection. Plus Replimune's Tudriqev wins accelerated FDA approval in a
FDA approved Replimune's Tudriqev for advanced melanoma after two rejections - and over its own reviewers' written objections. Plus Moderna's mRNA flu vaccine mFlusiva clears for adults 50 and older with a split label, I
Merck posted $16.61B in Q2 revenue and $8.37B in Keytruda sales — then cut profit guidance on acquisition charges. Alex and Maya break down the oral PCSK9 approval, the planned sacituzumab tirumotecan and Keytruda combin
Curium will pay up to $8.0 billion for Lantheus — Asubstantial cash payment per share plus additional contingent value rights tied to milestones stretching out several years. We break down theradiopharmaceutical consolid
AstraZeneca and Bristol Myers Squibb held months of merger talks valuing the combined company near $400 billion, per the Financial Times — a deal that would make AstraZeneca the world's fourth-largest drugmaker and draw
Ziltivekimab missed its primary endpoint in the 6,300-patient Phase 3 ZEUS trial, sending Novo Nordisk down 10% and dragging BioAge Labs down 60% and Monte Rosa Therapeutics down 30%. Also: AbbVie's Skyrizi posts $5.5 bi
An FDA advisory panel backed Replimune's RP1 by 10 to 3, overriding agency reviewers, with an approval decision due August 2nd. Also: the same-day panel voted Capricor's Duchenne cell therapy deramiocel down 9 to 3, John
FDA advisers recommended against Capricor's deramiocel — and the stock had already lost up to 60% before the vote. Also: Replimune falls nearly 40% as FDA reviewers call RP1's melanoma survival data uninterpretable ahead
FDA reviewers say Replimune's IGNYTE overall survival analysis is "not interpretable" days before Thursday's advisory committee — shares fell more than 32% to $5.78. We break down what it means for RP1, Opdivo combinatio
Capricor fell roughly 67% after FDA briefing documentsquestioned deramiocel's efficacy days before its advisory committee — and the company's rebuttal is a fight over which statistical analysis plan governs. Webreak down
Amgen told the FDA no — a blinded Duke re-analysis of ADVOCATE met noninferiority at 68.1% versus 67.1% but lost superiority, and the deadline is July 29. We unpack the avacopan withdrawal fight, the ChemoCentryx acquisi
Detected from recent episode content. Sponsor presence is a real signal of listener purchasing power and show monetisation.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes is hosted by Unknown Host. The show is categorised under science (life) and has published 128 episodes.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes has published 128 episodes.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes regularly covers science, life. It sits in the science category, with a life focus.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes average 11 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched today.